Search

H Lundbeck A-S

Затворен

34.66 -3.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.6

Максимум

35.9

Ключови измерители

By Trading Economics

Приходи

562M

1.2B

Продажби

694M

6.2B

P/E

Средно за сектора

10.121

38.156

EPS

1.53

Дивидентна доходност

2.81

Марж на печалбата

18.476

Служители

5,700

EBITDA

811M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.81%

2.50%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3.8B

33B

Предишно отваряне

38.11

Предишно затваряне

34.66

H Lundbeck A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.07.2025 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

EQT: To Spend Y407.82B for Tender Offer

29.07.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

EQT: Tender Offer Price Is Y5,700 a Share

29.07.2025 г., 23:54 ч. UTC

Придобивния, сливания и поглъщания

EQT To Start Tender Offer for Fujitec

29.07.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29.07.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Steady Ahead of FOMC Decision -- Market Talk

29.07.2025 г., 22:57 ч. UTC

Пазарно говорене

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29.07.2025 г., 22:50 ч. UTC

Пазарно говорене

Mondelez Warns of Price Increases in North America -- Market Talk

29.07.2025 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29.07.2025 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29.07.2025 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29.07.2025 г., 22:35 ч. UTC

Печалби

IGO Maintains Nova Life of Mine Production Guidance

29.07.2025 г., 22:35 ч. UTC

Печалби

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29.07.2025 г., 22:35 ч. UTC

Печалби

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29.07.2025 г., 22:34 ч. UTC

Печалби

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29.07.2025 г., 22:34 ч. UTC

Печалби

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29.07.2025 г., 22:34 ч. UTC

Пазарно говорене
Печалби

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29.07.2025 г., 22:33 ч. UTC

Печалби

IGO Had A$279.7 Million of Cash at End-June

29.07.2025 г., 22:33 ч. UTC

Печалби

IGO 4Q Underlying Free Cash A$2.4 Million

29.07.2025 г., 22:33 ч. UTC

Печалби

IGO FY Sales Revenue A$512.5 Million

29.07.2025 г., 22:33 ч. UTC

Печалби

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29.07.2025 г., 22:32 ч. UTC

Печалби

IGO FY Nickel Production 17,173 Tons

29.07.2025 г., 22:32 ч. UTC

Печалби

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29.07.2025 г., 22:32 ч. UTC

Печалби

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29.07.2025 г., 22:31 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

29.07.2025 г., 22:31 ч. UTC

Пазарно говорене
Печалби

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29.07.2025 г., 22:31 ч. UTC

Печалби

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29.07.2025 г., 22:31 ч. UTC

Печалби

IGO FY Spodumene Production 1.48 Million Tons

29.07.2025 г., 22:30 ч. UTC

Печалби

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29.07.2025 г., 22:30 ч. UTC

Печалби

IGO 4Q Underlying Ebitda A$62 Million

29.07.2025 г., 22:22 ч. UTC

Печалби

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

H Lundbeck A-S Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.